兰州大学机构库 >学院待认领
托伐普坦治疗心力衰竭有效性和安全性的系统评价
Alternative TitleTolvaptan for Heart Failure: A Systematic Review
元朝波
Thesis Advisor王志禄
2015-05-29
Degree Grantor兰州大学
Place of Conferral兰州
Degree Name硕士
Keyword托伐普坦 心力衰竭 Meta-分析 系统评价 随机对照试验
Abstract【目的】系统评价托伐普坦(tolvaptan, TOL)治疗心力衰竭(heart failure, HF)患者的有效性以及安全性。【方法】依据Cochrane Meta分析的文献资料检索方法,计算机检索PubMed、EMbase、Web of Science、The Cochrane Library、CBM、CNKI、VIP和WanFang Data,检索时限均从建库至2013年10月。由两名评价者按照纳入与排除标准以及Cochrane 协作网推荐的方法独立筛选文献、提取资料并评价纳入研究的方法学质量后,采用RevMan 5.2.3软件进行Meta 分析。【结果】本研究共纳入8个临床RCTs文献资料,总共录入4908例心力衰竭患者。本Meta分析的研究结果显示:①治疗效果:托伐普坦治疗组治疗前后患者的血清钠离子水平差值大于安慰剂组(MD=2.99, 95%CI=1.74~4.24, P=0.000);其体质量差值大于安慰剂组(MD=-0.81, 95%CI=-0.92~-0.70, P=0.000);其呼吸困难或肺淤血改善情况可能会优于安慰剂组(OR=1.34, 95%CI=1.17~1.55, P=0.000);其外周水肿改善情况与安慰剂组可能相似(OR=1.96, 95%CI=0.88~4.37, P=0.100)。②安全性:安慰剂组不良反应发生率显著低于托伐普坦治疗组(OR=1.36, 95%CI=1.15~1.61, P=0.000)。【结论】托伐普坦在治疗心力衰竭患者时能够有效地治疗及防止低钠血症的发生,并且还能够有效地减轻心力衰竭患者的体质量,尽管托伐普坦在治疗心力衰竭患者时会出现一些不良反应,但是其较严重的不良反应发生率低,患者的耐受性较好。
Other Abstract【Objective】To systematically review the efficacy and safety of tolvaptan for the patients with heart failure.【Methods】On the basis of the literature retrieval method according to the Cochrane Meta-analysis, such databases as Web of Science、The Cochrane Library、PubMed、EMbase、CNKI、CBM、WanFang Data and VIP were searched electronically, from inception to October 2013, for relevant studies. Two reviewers independently screened literature, extracted data, and assessed the methodological quality of the included studies according to the inclusion and exclusion criteria as well as the methods recommended by the Cochrane Collaboration. And then, employ RevMan 5.2.3 software to perform Meta-analysis.【Results】8 trials involving 4908 patients were included. The results of this Meta-analysis showed that tolvaptan was more effective than placebo in increasing the serum sodium concentration(MD=3.63, 95%CI 3.32 to 3.94, P=0.000),in decreasing body weight(MD=-0.81, 95%CI -0.92 to -0.70, P=0.000)and possibly in the improvement of dyspnea or pulmonary congestion(OR=1.34, 95%CI 1.17 to 1.55, P=0.000). However, there was no significant difference in peripheral edema between tolvaptan and placebo possibly(OR=1.96, 95%CI 0.88 to 4.37, P=0.100).On the other side, the tolvaptan group was lower than the placebo group significantly on the incidence of adverse events(OR=1.36, 95%CI 1.15 to 1.61, P=0.000).【Conclusion】Tolvaptan is effective for the patients with heart failure, and patients can tolerance the adverse events well.
URL查看原文
Language中文
Document Type学位论文
Identifierhttps://ir.lzu.edu.cn/handle/262010/222616
Collection学院待认领
Affiliation临床医学院
Recommended Citation
GB/T 7714
元朝波. 托伐普坦治疗心力衰竭有效性和安全性的系统评价[D]. 兰州. 兰州大学,2015.
Files in This Item:
There are no files associated with this item.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
Altmetrics Score
Google Scholar
Similar articles in Google Scholar
[元朝波]'s Articles
Baidu academic
Similar articles in Baidu academic
[元朝波]'s Articles
Bing Scholar
Similar articles in Bing Scholar
[元朝波]'s Articles
Terms of Use
No data!
Social Bookmark/Share
No comment.
Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.